ICI drugs target the co-inhibitory receptors present on T cells, such as cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) or their ligand (PD-L1) expressed on cancer cells, by selectively blocking their interaction. Here, CTLA4 is linked to cancer.